{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:26:28Z","timestamp":1790810788517,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003050","name":"Ministry of Economy, Trade and Industry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>From a clinical perspective, prostate-specific membrane antigen (PSMA) is a valuable target for both diagnosis and radioligand therapy (RLT) of prostate cancer. The term \u2018specific\u2019 has been used to characterize a histologic hallmark of overexpression in the membrane of most prostate cancer. Many PSMA ligands have been developed since the previous decade and have been used in several clinical trials and clinical studies. However, procedure, specification, protocol, interpretation criteria, radiation dose, and cost-effectiveness of PSMA ligands have not been fully explained. Regardless of worldwide use of promising PSMA-ligand PET and RLT, it has not been approved in Japan. Expedited introduction of PSMA-ligand PET and RLT to Japan and implementation of clinical study are eager for many patients with prostate cancer.<\/jats:p>","DOI":"10.1093\/jjco\/hyaa004","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T07:16:17Z","timestamp":1578381377000},"page":"349-356","source":"Crossref","is-referenced-by-count":41,"title":["Prostate-specific membrane antigen (PSMA)\u2013ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer"],"prefix":"10.1093","volume":"50","author":[{"given":"Ukihide","family":"Tateishi","sequence":"first","affiliation":[{"name":"Department of Diagnostic Radiology, Tokyo Medical and Dental University, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"key":"2020041702353547100_ref1","first-page":"4787","article-title":"Identification, purification, and subcellular localization of prostate-specific membrane antigen PSMA protein in the LNCaP prostatic carcinoma cell line","volume":"58","author":"Grauer","year":"1998","journal-title":"Cancer Res"},{"key":"2020041702353547100_ref2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.drudis.2007.07.010","article-title":"Progress in the discovery and development of glutamate carboxypeptidase II inhibitors","volume":"12","author":"Tsukamoto","year":"2007","journal-title":"Drug Discov Today"},{"key":"2020041702353547100_ref3","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-07-1517","article-title":"N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: A new imaging probe for prostate cancer","volume":"14","author":"Mease","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2020041702353547100_ref4","doi-asserted-by":"crossref","first-page":"7645","DOI":"10.1158\/1078-0432.CCR-11-1357","article-title":"2-(3-1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA based PET imaging agent for prostate cancer","volume":"17","author":"Chen","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2020041702353547100_ref5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1021\/acs.bioconjchem.6b00195","article-title":"[(18)F]fluoroethyl triazole substituted PSMA inhibitor exhibiting rapid normal organ clearance","volume":"27","author":"Chen","year":"2016","journal-title":"Bioconjug Chem"},{"key":"2020041702353547100_ref6","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer","volume":"56","author":"Bene\u0161ov\u00e1","year":"2015","journal-title":"J Nucl Med"},{"key":"2020041702353547100_ref7","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00259-016-3556-5","article-title":"Synthesis and pre-clinical evaluation of a new class of high-affinity 18F labeled PSMA ligands for detection of prostate cancer by PET imaging","volume":"44","author":"Kelly","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2020041702353547100_ref8","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2967\/jnumed.118.220715","article-title":"Phase I study of CTT1057, an 18F-Labeled imaging agent with Phosphoramidate Core targeting prostate-specific membrane antigen in prostate cancer","volume":"60","author":"Behr","year":"2019","journal-title":"J Nucl Med"},{"key":"2020041702353547100_ref9","first-page":"1635","article-title":"Preclinical dosimetry and human biodistribution of 18F-rhPSMA-7 and 18F-rhPSMA-7.3","volume":"60","author":"Oh","year":"2019","journal-title":"J Nucl Med"},{"key":"2020041702353547100_ref10","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/cas.13911","article-title":"Initial evaluation of PET\/CT with 18F-FSU-880 targeting prostate-specific membrane antigen in prostate cancer patients","volume":"110","author":"Saga","year":"2019","journal-title":"Cancer Sci"},{"key":"2020041702353547100_ref11","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/bc200279b","article-title":"68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging","volume":"23","author":"Eder","year":"2012","journal-title":"Bioconjug Chem"},{"key":"2020041702353547100_ref12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2191-219X-2-23","article-title":"A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer","volume":"2","author":"Sch\u00e4fer","year":"2012","journal-title":"EJNMMI Res"},{"key":"2020041702353547100_ref13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13550-014-0063-1","article-title":"Synthesis and preclinical evaluation of DOTAGA conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer","volume":"4","author":"Weineisen","year":"2014","journal-title":"EJNMMI Res"},{"key":"2020041702353547100_ref14","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","article-title":"Linker modification strategies to control the prostate-specific membrane antigen (PSMA)\u2014Targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors","volume":"59","author":"Bene\u0161ov\u00e1","year":"2016","journal-title":"J Med Chem"},{"key":"2020041702353547100_ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0145755","article-title":"(R)-NODAGA-PSMA: A versatile precursor for radiometal labeling and nuclear imaging of PSMA-positive tumors","volume":"10","author":"Gourni","year":"2015","journal-title":"PLoS One"},{"key":"2020041702353547100_ref16","doi-asserted-by":"crossref","first-page":"E710","DOI":"10.3390\/cancers11050710","article-title":"Detection rate of 18F-Labeled PSMA PET\/CT in biochemical recurrent prostate cancer: A systematic review and a meta-analysis","volume":"11","author":"Treglia","year":"2019","journal-title":"Cancers"},{"key":"2020041702353547100_ref17","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2967\/jnumed.116.185538","article-title":"PSA-stratified performance of (18)F- and (68)Ga-PSMA PET in patients with biochemical recurrence of prostate cancer","volume":"58","author":"Dietlein","year":"2017","journal-title":"J Nucl Med"},{"key":"2020041702353547100_ref18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00259-017-3818-x","article-title":"Clinical impact of PSMA-based (18)F-DCFBC PET\/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy","volume":"45","author":"Mena","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2020041702353547100_ref19","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2967\/jnumed.117.196329","article-title":"Biochemical recurrence of prostate cancer: Initial results with [(18)F]PSMA-1007 PET\/CT","volume":"59","author":"Giesel","year":"2018","journal-title":"J Nucl Med"},{"key":"2020041702353547100_ref20","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s00259-018-4089-x","article-title":"Diagnostic performance of (18)F-PSMA-1007 PET\/CT in patients with biochemical recurrent prostate cancer","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2020041702353547100_ref21","first-page":"jnumed.119.226381","article-title":"A prospective study on (18)F-DCFPyL PSMA PET\/CT imaging in biochemical recurrence of prostate cancer","volume":"pii","author":"Rousseau","year":"2019","journal-title":"J Nucl Med"},{"key":"2020041702353547100_ref22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2967\/jnumed.118.212233","article-title":"Detection efficacy of (18)F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"key":"2020041702353547100_ref23","first-page":"S0302-2838(19)30095-8","article-title":"Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: A systematic review and meta-analysis","volume":"pii","author":"Perera","year":"2019","journal-title":"Eur Urol"},{"key":"2020041702353547100_ref24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12885-018-5200-1","article-title":"Randomized prospective phase III trial of 68Ga-PSMA-11 PET\/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]","volume":"19","author":"Calais","year":"2019","journal-title":"BMC Cancer"},{"key":"2020041702353547100_ref25","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00259-017-3924-9","article-title":"PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer","volume":"45","author":"Derlin","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2020041702353547100_ref26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.urology.2017.05.058","article-title":"Bone scan index is an independent predictor of time to castration-resistant prostate cancer in newly diagnosed prostate cancer: A prospective study","volume":"108","author":"Zacho","year":"2017","journal-title":"Urology"},{"key":"2020041702353547100_ref27","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.2967\/jnumed.116.177030","article-title":"A Preanalytic validation study of automated bone scan index: Effect on accuracy and reproducibility due to the procedural Variabilities in bone scan image acquisition","volume":"57","author":"Anand","year":"2016","journal-title":"J Nucl Med"},{"key":"2020041702353547100_ref28","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00259-013-2660-z","article-title":"Comparison of PET\/CT and PET\/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: Initial experience","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2020041702353547100_ref29","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s00259-017-3854-6","article-title":"Simultaneous whole-body 18F-PSMA-1007-PET\/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: A pilot study","volume":"45","author":"Freitag","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2020041702353547100_ref30","doi-asserted-by":"crossref","first-page":"006","DOI":"10.2967\/jnumed.115.168443","article-title":"177Lu-Labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J Nucl Med"},{"key":"2020041702353547100_ref31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.juro.2016.02.2969","article-title":"Systemic radioligand therapy with (177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer","volume":"196","author":"Heck","year":"2016","journal-title":"J Urol"},{"key":"2020041702353547100_ref32","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","article-title":"Targeted a-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: Dosimetry estimate and empiric dose finding","volume":"58","author":"Kratochwil","year":"2017","journal-title":"J Nucl Med"},{"key":"2020041702353547100_ref33","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00259-017-3657-9","article-title":"213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer","volume":"44","author":"Sathekge","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2020041702353547100_ref34","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2967\/jnumed.116.174300","article-title":"(2S)-2-(3-(1-Carboxy-5-(4-211At-astatobenzamido)pentyl)Ureido)-pentanedioic acid for PSMA targeted alpha-particle radiopharmaceutical therapy","volume":"57","author":"Kiess","year":"2016","journal-title":"J Nucl Med"},{"key":"2020041702353547100_ref35","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J Urol"},{"key":"2020041702353547100_ref36","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s00259-017-3780-7","article-title":"Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging","volume":"44","author":"Sheikhbahaei","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2020041702353547100_ref37","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00259-014-2915-3","article-title":"[(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice","volume":"42","author":"Krohn","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/4\/349\/33096157\/hyaa004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/4\/349\/33096157\/hyaa004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T02:35:53Z","timestamp":1587090953000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/50\/4\/349\/5799065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,3,9]]},"published-print":{"date-parts":[[2020,4,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa004","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2020,3,9]]}}}